Pfizer and Biontech announced that the efficacy portion of the Corona vaccine trial has been completed, indicating that the vaccine is 95% effective.
According to Arabnet, the two companies said they plan to submit an application to the Food and Drug Administration for permission to use in emergency situations within days, and will also submit it to the regulatory authorities in All over the world.
The results come just over a week after the two companies announced that an earlier analysis of the study showed that the vaccine reduced infections by more than 90%, and only days after Moderna's announcement , That a similar vaccine reduced infection by 94.5%.
The combined results raise hopes that vaccines will be widely available sometime next year, and perhaps also, that other vaccines that combat the disease will also prove effective.
Today is a great day for science and humanity, Dr. Albert Burla, Chairman and CEO of Pfizer, said the first set of results from the third phase of the Covid-19 vaccine trial provides The preliminary evidence for the ability of our vaccine to prevent corona.
We have reached this critical milestone in our vaccine development program at a time the world needs the most, with infection rates in record numbers.
The discovery that 95% of infections have been prevented by the Pfizer vaccine may spark politicians and public health leaders and potentially put an end to the epidemic.
More than 43,000 people participated in the Phase 3 trials.
Pfizer stated that collecting the required safety data will take until the third week of November, then the file will be submitted to the regulators for approval.
by company; Expedited licensing could mean giving healthcare workers the first doses by the end of the year.
